Multi–Cancer Early Detection Test
Spot early signs of common and aggressive cancers, by analysing DNA shed by cancer cells (ctDNA), with a single blood draw.
What is
ctDNA Technology?
Circulating tumour DNA (ctDNA) technology is used in non-invasive, multi-cancer early detection (MCED) tests to detect fragments of DNA from tumour cells that are released into the bloodstream. Through a simple blood test, ctDNA can provide early detection for common and aggressive cancers.
All cells carry DNA
Both healthy cells and cancer cells contain DNA.
Tumour cells shed DNA fragments
When cancer cells grow or die, they release small pieces of their DNA (called circulating tumour DNA, or ctDNA) into the bloodstream.
A blood test detects ctDNA
This may provide early clues about the presence of cancer, sometimes even before symptoms arise.
ctDNA Test Process
STEP 01
Request the test
Schedule your appointment with us. During your visit, we will conduct a simple blood draw. No fasting or special preparation is needed.
STEP 02
Sequencing of ctDNA
Your sample is sent to a specialised lab for processing. Using next-generation sequencing techniques, the lab analyses your blood for ctDNA fragments that may indicate the presence of cancer.
STEP 03
Returning results
You’ll receive your results within 4 to 6 weeks via email. If necessary, a doctor will review the findings with you and recommend the next steps.
Who Should Consider
ctDNA Screening?
ctDNA testing provides valuable insights for anyone who wants to take charge of their health.
We recommend ctDNA testing if you:
- Are aged 40 years or older
- Have a family history of cancer
- Have known genetic mutations that increase your risk of cancer
- Have unhealthy habits like smoking or drinking alcohol
Note: ctDNA screening is not recommended for pregnant women or patients undergoing cancer treatment, or those with history of bone marrow transplant or blood transfusion within 3 months.
Have further questions?
Simply reach out to us to learn more
Benefits of ctDNA in
Multi–cancer Early Detection
Non-invasive and Convenient
Only requires one single blood draw during a healthcare visit.
High Accuracy
Incorporates next-generation sequencing and AI technologies to analyse multiple features of ctDNA.
Early Detection
Helps to identify cancer signals at an early stage, which aids treatment planning.
Efficiency
Capability to test for cancers that do not have recommended screenings to improve patient outcomes.
Make An Appointment
Complete Healthcare International (CHI) was founded to provide high-quality, personalised healthcare services to both international and local families in Singapore.
Frequently Asked Questions
ctDNA is a non-invasive screening tool that examines circulating tumor DNA (ctDNA) in the blood. It uses next-generation sequencing and artificial intelligence to detect potential cancer-associated biomarkers linked to several common cancers. This test is designed to support earlier medical evaluation through a single blood draw.
Detecting cancer at an earlier stage often allows for more effective treatment options and better outcomes. Early detection may increase the chances of managing the condition before it progresses, supporting improved quality of life and long-term health.
ctDNA testing is designed to screen for signals associated with commonly occurring cancers, including:
- Lung
- Breast
- Colorectal
- Stomach
- Liver
- Esophageal
- Ovarian
- Pancreatic
- Prostate
- Nasopharyngeal
The test is suitable for both men and women and helps support earlier medical evaluation if potential cancer signals are detected.
The ctDNA test involves a single blood draw, typically done during a routine clinic visit. The sample is then sent to a specialized laboratory, where it is analyzed for circulating tumor DNA (ctDNA) that may indicate the presence of cancer-related signals.
Results are typically available within 4 to 6 weeks, after which further clinical consultation may be recommended if necessary.
ctDNA is generally recommended for individuals aged 40 and above, especially those with elevated cancer risk (family history, diet and/or lifestyle).
Speak with a healthcare professional to determine if this screening is appropriate for you.
While ctDNA is primarily recommended for those aged 40 and above, it may also be considered for younger individuals who have:
- A strong family history of cancer
- Known genetic mutations associated with higher cancer risk
- Chronic medical conditions such as Hepatitis B or C
- Other clinically identified high-risk factors
Speak with a healthcare professional to assess suitability based on personal risk profile.
If ctDNA detects circulating tumor DNA (ctDNA) signals:
- Additional diagnostic tests, such as imaging studies, will be needed to confirm the presence of cancer.
- Your healthcare provider will discuss the results and recommend appropriate follow-up investigations.
- The test result is a screening indicator, not a definitive diagnosis.
- Early consultation helps guide timely and informed medical decisions.
- It is generally recommended to consider testing annually, especially for individuals with a higher cancer risk.
- Your healthcare provider may advise a different testing schedule based on your personal health profile and risk factors.
- Regular screening supports ongoing monitoring but should be combined with other recommended health checks.
- ctDNA is intended to complement existing cancer screening methods.
- It is not a replacement for established screening programs such as mammograms, colonoscopies, or Pap smears.
- The test should be used alongside other recommended screenings as part of a comprehensive health plan.
- Always follow your doctor’s advice on appropriate cancer screening for your individual needs.
© 2025 Complete Healthcare International. All Rights Reserved. Web Design by iClick Media